Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated Akkermansia muciniphila
- Development stage
- Unknown
- Lead developer
- Shanghai East Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Inactivated Akkermansia muciniphila (specifically strain Akk11 in the context of Shanghai East Hospital) is a microbial therapy consisting of pasteurized or heat-killed bacteria. Unlike live biotherapeutics, the inactivated form of this gut commensal has been shown to retain or even enhance its metabolic benefits, particularly in improving intestinal barrier function and insulin sensitivity. The primary mechanism involves the interaction of the outer membrane protein Amuc_1100 with Toll-like receptor 2 (TLR2) on the intestinal epithelium. This interaction triggers signaling pathways that strengthen tight junctions and reduce metabolic endotoxemia. It is currently being investigated in Phase 4 clinical trials for the treatment of polycystic ovary syndrome (PCOS) and obesity, often as an adjunct to metformin therapy.
- Other names
- pasteurized Akkermansia muciniphilaheat-killed Akkermansia muciniphilaAkkermansia muciniphila (inactivated)
02
Targets
FFAR3 (Free fatty acid receptor 3)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)FFAR2TLR1
Beyond the preview
Go deeper on inactivated Akkermansia muciniphila.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated Akkermansia muciniphila.